Doctor’s Guide -- NEW YORK -- October 27, 2010 -- Health Canada has approved dabigatran etexilate (Pradax) for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate.
Doctor’s Guide -- NEW YORK -- October 27, 2010 -- Health Canada has approved dabigatran etexilate (Pradax) for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate.